

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 16 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 17 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:57:28 ON 13 JAN 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 09:57:36 ON 13 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10522250 updated.str



8
11
12

19
11
12

chain nodes :

9 11 12

ring nodes :

1 2 3 4 5 6 7 8
chain bonds :
2-9 11-12
ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8
exact/norm bonds :
1-2 1-5 2-3 2-9 3-4 3-6 4-5 4-8 6-7 7-8 11-12
isolated ring systems :
containing 1 :

G1:O,S,N,SO2,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS
12:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.48	0.70

FILE 'CAPLUS' ENTERED AT 09:57:57 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s ll sss full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:58:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 651 TO ITERATE

100.0% PROCESSED 651 ITERATIONS

550 ANSWERS

SEARCH TIME: 00.00.01

L2 550 SEA SSS FUL L1

L3 22 L2

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2008:888806 CAPLUS Full-text

DOCUMENT NUMBER: 149:200948

TITLE: Preparation of substituted arylamine derivatives
useful for the treatment of pain, inflammation and
cancer

INVENTOR(S): Barbosa, Joseph; Baugh, Simon D. P.; Han, Qiang;
Lombardo, Victoria K.; Nguyen, Huy Van; Pabba, Praveen
K.; Terranova, Kristen M.

PATENT ASSIGNEE(S): Lexicon Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 111pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008089307	A2	20080724	WO 2008-US51273	20080117
WO 2008089307	A3	20081106		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

US 20080194557
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
GI


A1 20080814
MARPAT 149:200948

US 2008-15714
US 2007-881090P

20080117
P 20070118



- AB This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compds. and pharmaceutical compns. useful in such methods. Compds. of formula I [Q1 = CR1, CHR1, N or NR1; Q2 = CR1, CHR1, N or NR1; X = S, O, C(R4R5) or N(R4); Y = C(R4), C(R4R5), N or N(R4); A = bond, CH2, C(O) or SO2; R1 and R3 independently = H, CN, NO2, halo, (un)substituted alkyl, aryl, alkylaryl, arylalkyl, etc.; R2 = H or (un)substituted alkyl; R4 and R5 independently = H or (un)substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl; n = 1-4; m = 1-5], and their pharmaceutically acceptable salts or solvates, are prepared and disclosed as potent Δ^5 -desaturase inhibitors. Thus, e.g., N-(3-chlorophenyl)isoquinolin-1-amine was prepared by condensation reaction of 1-chloroisoquinoline with 3-chloroaniline. I are potent Δ^5 -desaturase inhibitors, e.g., some compds. had IC50 values of < 250 nM. Certain compds. inhibited Δ^5 -desaturase in vivo by greater than 75% at about 60 mpk.
- IT 1041614-39-4P, (5-Chloro-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl) (3-chlorophenyl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted arylamine derivs. useful for the treatment of pain, inflammation and cancer)
- RN 1041614-39-4 CAPLUS
- CN 1H-Thieno[2,3-c]pyrazol-3-amine, 5-chloro-N-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:887545 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 149:200945
TITLE: Preparation of substituted arylamine derivatives
useful for the treatment of body composition disorders
INVENTOR(S): Barbosa, Joseph; Baugh, Simon D. P.; Han, Qiang;
Lombardo, Victoria K.; Nguyen, Huy Van; Pabba, Praveen


K.; Terranova, Kristen M.
 Lexicon Pharmaceuticals, Inc., USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 106pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008089310	A2	20080724	WO 2008-US51277	20080117
WO 2008089310	A3	20081030		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080200458 A1 20080821 US 2008-15728 20080117
 PRIORITY APPLN. INFO.: US 2007-880990P P 20070118
 OTHER SOURCE(S): MARPAT 149:200945
 GI



AB This invention relates to methods of treating, managing and preventing body composition disorders, such as obesity and diabetes, and to compds. and pharmaceutical compns. useful in such methods. Compds. of formula I [Q¹ = CR¹, CHR¹, N or NR¹; Q² = CR¹, CHR¹, N or NR¹; X = S, O, C(R⁴R⁵) or N(R⁴); Y = C(R⁴), C(R⁴R⁵), N or N(R⁴); A = bond, CH₂, C(O) or SO₂; R¹ and R³ independently = H, CN, NO₂, halo, (un)substituted alkyl, aryl, alkylaryl, arylalkyl, etc.; R² = H or (un)substituted alkyl; R⁴ and R⁵ independently = H or (un)substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl; n = 1-4; m = 1-5], and their pharmaceutically acceptable salts or solvates, are prepared and disclosed as potent Δ⁵-desaturase inhibitors. Thus, e.g., N-(3-chlorophenyl)isoquinolin-1-amine was prepared by condensation reaction of 1-chloroisoquinoline with 3-chloroaniline. I are potent Δ⁵-desaturase inhibitors, e.g., some compds. had IC₅₀ values of < 250 nM. Certain compds. inhibited Δ⁵-desaturase in vivo by greater than 75% at about 60 mpk.


IT 1041614-33-4P, (5-Chloro-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl)(3-chlorophenyl)amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of substituted arylamine derivs. useful for the treatment of pain, inflammation and cancer)

RN 1041614-39-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 5-chloro-N-(3-chlorophenyl)-1-methyl-
(CA INDEX NAME)



L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:173028 CAPLUS Full-text

DOCUMENT NUMBER: 148:426791

TITLE: Synthesis of 3-substituted-1-methyl-1H-thieno[2,3-c]pyrazoles

AUTHOR(S): Toto, Patrick; Chenault, Jacques; El Hakmaoui, Ahmed; Akssira, Mohamed; Guillaumet, Gerald

CORPORATE SOURCE: Analytic and Organic Chemistry Institute, UMR CNRS, University of Orleans, Orleans, Fr.

SOURCE: Synthetic Communications (2008), 38(5), 674-683

CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:426791

AB The authors reported a simple and practical six-step synthesis of new 1-methyl-1H-thieno[2,3-c]pyrazoles from 3-amino-1H-pyrazole-4-carboxylic acid Et ester.

IT 1017802-97-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of substituted-methyl-thienopyrazoles from aminopyrazole-carboxylic acid Et ester in six-steps)

RN 1017802-97-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

3-amino-4-[[5-(ethoxycarbonyl)-4-hydroxy-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl]amino]-1-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1146039 CAPLUS Full-text
 DOCUMENT NUMBER: 147:440293
 TITLE: Use of thienopyrazole derivative ABL kinase inhibitors
 for the treatment of resistant tumors, and screening
 method
 INVENTOR(S): Fancelli, Daniele; Isacchi, Antonella; Modugno,
 Michele; Moll, Jurgen; Rusconi, Luisa; Soncini,
 Chiara; Lupi, Rosita
 PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
 SOURCE: PCT Int. Appl., 43pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007113198	A2	20071011	WO 2007-EP53013	20070329
WO 2007113198	A3	20080320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 2007380	A2	20081231	EP 2007-727485	20070329
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			EP 2006-112026	A 20060330
			WO 2007-EP53013	W 20070329

OTHER SOURCE(S): MARPAT 147:440293

AB The invention provides low mol. weight compds., namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compds. are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compds. of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, e.g. imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compds. capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

IT 862555-81-5 862555-87-1 862556-93-2
 862556-96-5 862556-99-8 862557-05-9
 862557-17-3 862557-20-8 862557-23-1
 862557-28-6 862557-30-0 862557-32-2
 862557-34-4 862557-39-9 862557-41-3
 862557-43-5 862557-54-8 862557-55-9
 862557-58-2 862557-61-7 862557-64-0
 862557-75-3 862557-79-7 862557-81-1
 862557-83-3 862557-86-6 862557-88-8
 862557-92-4 862558-27-8 862558-40-5
 862558-44-9 862558-48-3 862558-50-7


862559-05-5 862559-07-7 862559-08-8
 862559-17-9 862559-20-4 862559-21-5
 862559-30-6 862559-32-3 862559-34-9
 862559-59-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(thienopyrazole derivative ABL kinase inhibitors for treatment of resistant
 tumors, and screening method)


RN 862555-81-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX
 NAME)




RN 862555-87-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX
 NAME)




RN 862556-93-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-
 piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862556-96-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)-
 (CA INDEX NAME)




RN 862556-99-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862557-05-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862557-17-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862557-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA
INDEX NAME)




RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA
INDEX NAME)




RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA
INDEX NAME)




RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA
INDEX NAME)




RN 862557-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[[[(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-41-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-43-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-54-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-55-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-58-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-61-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA
INDEX NAME)




RN 862557-64-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidylmethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-
methylethyl]- (CA INDEX NAME)




RN 862557-75-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-79-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(dimethylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862558-27-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyloxy)benzoyl]amino]- (CA INDEX NAME)




RN 862558-40-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-
methylethyl]- (CA INDEX NAME)




RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[[[(1-
methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-
phenylethyl)- (CA INDEX NAME)



RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862559-05-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-07-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 862559-08-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-17-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-20-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-21-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)



RN 862559-59-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2007:85753 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:184454

TITLE: Preparation of 1H-thieno[2,3-c]pyrazoles as kinase,
particularly Aurora kinases and IGF-1R inhibitors for
treating cancer

INVENTOR(S): Fancelli, Daniele; Moll, Juergen; Pulici, Maurizio;
Quartieri, Francesca; Bandiera, Tiziano

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009898	A1	20070125	WO 2006-EP64055	20060710
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1904503	A1	20080402	EP 2006-764123	20060710
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			EP 2005-106602	A 20050719
			WO 2006-EP64055	W 20060710
OTHER SOURCE(S):	MARPAT 146:184454			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = hetero/aryl on which the substituent -NHZR5 is at the ortho position to the CONH linker; R1, R2 = independently H, alkyl, CONH2, etc.; or R1CR2 = cycloalkyl; R3 = H, halo, OH, CN, alkyl, di/alkylamino, alkoxy; R4 = H, halo, alkoxy, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, etc.; Z = a bond, CO, C(=O)NH; R5 = H, (un)substituted cycloalkyl, alk(en)yl, aryl, etc.; and their isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts] were prepared as protein kinase, especially Aurora kinases and IGF-1R, inhibitors. I, and their pharmaceutical compns., are useful in the treatment of diseases caused by and/or associated with a dysregulated protein kinase, such as cancer and cell proliferation disorders. E.g., a multi-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate was given for thienopyrazole II. II was tested as Aurora-2 kinase inhibitor (IC50 = 6 nM) and for its HCT-116 colon cancer cell antiproliferative effect (IC50 = 7 nM).

IT 921768-48-1P, 3-[2-[[{(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-49-2P, 3-[2-[[{(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-50-5P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-51-6P, 3-[2-[[{(Tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-52-7P,

3-[2-[[5-Methyl-1H-pyrazol-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-53-8P, 3-[2-[[Furan-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-54-9P, 3-[2-[[Furan-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-55-0P, 3-[2-[[2-Ethyl-5-methyl-2H-pyrazol-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-56-1P, 3-[2-[(Isobutanoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-57-2P, 3-[2-[[2-Methyl-2H-pyrazol-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-58-3P, 3-[2-[[1-Methyl-1H-pyrazol-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-59-4P, 3-[2-[[1-Methyl-1H-pyrrol-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-60-7P, 3-[2-[[Thiazol-4-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-61-8P, 3-[2-[[1H-Pyrrol-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-62-9P, 3-[2-[[1H-Imidazol-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-63-0P 921768-64-1P, 3-[2-[[1-Methyl-1H-imidazol-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-65-2P, 3-[2-[(Phenylacetyl)amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-66-3P, 3-[2-[[Thien-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-67-4P, 3-[2-[[Thien-3-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-68-5P, 3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-69-6P, 3-[2-[(Tetrahydropyran-4-yl)amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-70-9P, 3-[2-(2-Fluorobenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-71-0P, 3-[2-[4-(4-Methylpiperazin-1-yl)benzoylamino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-72-1P, 3-[2-[[4-(Morpholin-4-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-73-2P, 3-[2-[[4-(Piperidin-1-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-74-3P, 3-[2-[[4-(Pyrrolidin-1-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-75-4P, 3-[2-(2-Methylbenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-76-5P, 3-[2-(2-Methoxybenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-77-6P, 3-[2-(4-Methylbenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-78-7P, 3-[2-(4-Methoxybenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-79-8P, 3-[2-(4-Fluorobenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-80-1P 921768-81-2P,

3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-82-3P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)benzoylamino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
 921768-83-4P, 3-[2-[(Tetrahydropyran-4-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-84-5P,
 3-[2-[(Furan-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-
 carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
 921768-85-6P, 3-[2-[(2-Ethyl-5-methyl-2H-pyrazol-3-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-86-7P
 921768-87-8P, 3-[4-(4-Methylpiperazin-1-yl)-2-[(tetrahydropyran-4-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 (1-methyl-1-phenylethyl)amide 921768-88-9P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[(5-methyl-1H-pyrazol-3-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 (1-methyl-1-phenylethyl)amide 921768-89-0P,
 3-[2-[(Furan-2-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-
 1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-90-3P, 3-[2-[(2-Ethyl-5-methyl-2H-pyrazol-3-
 yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-91-4P, 3-[4-(4-Methylpiperazin-1-yl)-2-[(1H-pyrrol-2-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 (1-methyl-1-phenylethyl)amide 921768-92-5P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)-4-(4-methylpiperazin-1-
 yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-93-6P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[(tetrahydropyran-4-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-94-7P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[(5-methyl-1H-pyrazol-3-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-95-8P,
 3-[2-[(Furan-2-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-
 1H-thieno[2,3-c]pyrazole-5-carboxylic acid 921768-96-9P,
 3-[2-[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]-4-(4-
 methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic
 acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-97-0P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[(1H-pyrrol-2-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-98-1P,
 3-[2-[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid benzylamide 921768-99-2P,
 3-[2-[(1H-Pyrrol-2-yl)carbonyl]amino]benzoyl]amino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid N-((R)-1-phenylethyl)amide
 921769-14-4P, 3-[2-[(5-Methylisoxazol-4-
 yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 (1-methyl-1-phenylethyl)amide 921769-15-5P,
 3-[2-[(5-Methylisoxazol-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
 921769-16-6P, 3-[2-[(5-Methylisoxazol-4-yl)carbonyl]amino]-4-(4-
 methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic
 acid (1-methyl-1-phenylethyl)amide 921769-17-7P,
 3-[2-[(5-Methylisoxazol-4-yl)carbonyl]amino]-4-(4-methylpiperazin-1-
 yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of thienopyrazoles as kinase inhibitors for
treating cancer)


RN 921768-48-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(1H-pyrrol-2-
ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-49-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(1H-pyrrol-2-
ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-50-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-
(1-methyl-1-phenylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-51-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-52-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-53-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(2-furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-54-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(3-furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-56-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-57-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-58-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-59-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-60-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(4-methylthiazol-5-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-61-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(1H-pyrrol-3-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-62-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(1H-imidazol-2-ylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-63-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-(benzoylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-64-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-65-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(2-phenylacetyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-66-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(2-thienylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-67-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(3-thienylcarbonyl)amino]benzoyl]amino]-
(CA INDEX NAME)




RN 921768-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-(acetylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX
NAME)



RN 921768-69-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(tetrahydro-2H-pyran-4-yl)amino]benzoyl]amino]-
(CA INDEX NAME)



RN 921768-70-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,


3-[[2-[(2-fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)



RN 921768-71-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,


N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-72-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4-morpholinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-73-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-
piperidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-74-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-75-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[2-methylbenzoyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 921768-76-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 921768-77-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(4-methylbenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 921768-78-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(4-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 921768-79-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(4-fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 921768-80-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-81-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-(acetylamino)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]-
(CA INDEX NAME)



RN 921768-82-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-
[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-83-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(tetrahydro-2H-pyran-4-
yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-84-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(2-
furanlycarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-85-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-N-(1-(2-fluorophenyl)-1-methylethyl)- (CA INDEX NAME)



RN 921768-86-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-, hydrochloride
(1:?) (CA INDEX NAME)


Double bond geometry as shown.



● x HCl


RN 921768-87-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-88-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-89-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-
N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-90-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[1-ethyl-3-methyl-1H-pyrazol-5-yl]carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921768-91-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-92-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-93-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[[4-(4-methyl-1-piperazinyl)-2-
[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX
NAME)



RN 921768-94-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[[4-(4-methyl-1-piperazinyl)-2-[[(5-
methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-95-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 921768-96-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[1-ethyl-3-methyl-1H-pyrazol-5-yl]carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 921768-97-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-98-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(phenylmethyl)-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA
INDEX NAME)



RN 921768-99-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1R)-1-phenylethyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 921769-14-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-
phenylethyl)- (CA INDEX NAME)




RN 921769-15-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,


N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921769-16-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921769-17-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)



IT 656235-16-6P, tert-Butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-


carboxylate 862559-62-4F 921767-86-4P
 921767-87-5P 921767-88-6P 921767-89-7P
 921767-90-0P, 3-(2-Aminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-
 carboxylic acid tert-butyl ester 921767-91-1F,
 3-(2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino)-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid tert-butyl ester 921767-92-2P
 921767-93-3P 921767-94-4P 921767-95-5P
 921767-96-6P 921767-97-7P 921767-98-8P
 921767-99-9P 921768-00-5P 921768-01-6P
 921768-02-7P 921768-03-8P 921768-04-9P,
 3-[2-[(1H-Pyrrol-2-yl)carbonylamino]benzoylamino]-1H-thieno[2,3-
 c]pyrazole-5-carboxylic acid tert-butyl ester 921768-05-0P
 921768-06-1P 921768-07-2P 921768-08-3P
 921768-09-4P 921768-10-7P 921768-11-8P
 921768-12-9P 921768-13-0P 921768-14-1P
 921768-15-2P 921768-16-3P 921768-17-4P,
 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-[(1H-pyrrol-2-
 yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
 ethyl ester 921768-18-5P,
 3-[2-[(5-Methylisoxazol-4-yl)carbonylamino]benzoylamino]-5-[(1-methyl-1-
 phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
 921768-19-6P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-
 [(tetrahydropyran-4-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-
 1-carboxylic acid ethyl ester 921768-20-9P,
 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-[(5-methyl-1H-pyrazol-3-
 yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
 ethyl ester 921768-21-0P,
 3-[2-[(Furan-2-yl)carbonylamino]benzoylamino]-5-[(1-methyl-1-
 phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
 921768-23-2P, 3-[2-[(2-Ethyl-5-methyl-2H-pyrazol-3-
 yl)carbonylamino]benzoylamino]-5-[(1-methyl-1-
 phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
 921768-25-4P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-
 methylpiperazin-1-yl)-2-[(1H-pyrrol-2-
 yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
 ethyl ester 921768-27-6P,
 3-[2-[(5-Methylisoxazol-4-yl)carbonylamino]-4-(4-methylpiperazin-1-
 yl)benzoylamino]-5-[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-
 c]pyrazole-1-carboxylic acid ethyl ester 921768-29-8P,
 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-
 [(tetrahydropyran-4-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-
 1-carboxylic acid ethyl ester 921768-31-2P,
 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-[(5-
 methyl-1H-pyrazol-3-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-
 carboxylic acid ethyl ester 921768-33-4P,
 3-[2-[(Furan-2-yl)carbonylamino]-4-(4-methylpiperazin-1-yl)benzoylamino]-
 5-[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic
 acid ethyl ester 921768-35-6P,
 3-[2-[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonylamino]-4-(4-
 methylpiperazin-1-yl)benzoylamino]-5-[(1-methyl-1-
 phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
 921768-36-7P, 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-
 [2-[(1H-pyrrol-2-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-
 carboxylic acid ethyl ester 921768-37-8P,
 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[(5-methylisoxazol-
 4-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
 ethyl ester 921768-38-9P,
 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[(tetrahydropyran-
 4-yl)carbonylamino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
 ethyl ester 921768-39-0P,

5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-40-3P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[[(furan-2-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-41-4P,
3-[2-[[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-5-[[1-(2-fluorophenyl)-1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-42-5P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-[[[(1H-pyrrol-2-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-43-6P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[[(5-methylisoxazol-4-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-44-7P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-[[[(tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-45-8P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-46-9P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[[(furan-2-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921768-47-0P,
3-[2-[[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-5-[[1-(2-fluorophenyl)-1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-00-0P 921769-02-0P 921769-03-1P,
5-[[1-Methyl-1-phenylethyl]carbamoyl]-3-(2-nitrobenzoylamino)thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-04-2P,
5-[[1-(2-Fluorophenyl)-1-methylethyl]carbamoyl]-3-(2-nitrobenzoylamino)thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-05-3P, 5-[[1-Methyl-1-phenylethyl]carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-nitrobenzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-06-4P,
5-[[1-Methyl-1-phenylethyl]carbamoyl]-3-[[2-nitro-4-[(pyrrolidin-1-yl)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-07-5P, 5-[[1-Methyl-1-phenylethyl]carbamoyl]-3-[[2-nitro-4-[[piperidin-1-yl)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-08-6P,
5-[[1-Methyl-1-phenylethyl]carbamoyl]-3-[4-[(morpholin-4-yl)methyl]-2-nitrobenzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-09-7P, 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-nitrobenzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-10-0P,
3-(2-Aminobenzoylamino)-5-[[1-methyl-1-phenylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-11-1P,
3-(2-Aminobenzoylamino)-5-[[1-(2-fluorophenyl)-1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-12-2P, 3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-5-[[1-methyl-1-phenylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester 921769-13-3P,
3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-5-[[1-(2-fluorophenyl)-1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of thienopyrazoles as kinase inhibitors for treating cancer)

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862559-62-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-86-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-nitrobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-87-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-88-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-aminobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX
NAME)




RN 921767-89-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-amino-4-(4-methyl-1-piperazinyl)benzoyl)amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-90-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(2-aminobenzoyl)amino]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 921767-91-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[(2-amino-4-(4-methyl-1-piperazinyl)benzoyl)amino]-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 921767-92-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-93-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-94-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[1-(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-95-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[1-(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921767-96-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[1-(2-furanylcarbonyl)amino]benzoyl]amino]-, 5-(1,1-dimethylethyl)
1-ethyl ester (CA INDEX NAME)




RN 921767-97-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-,
5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)



RN 921767-98-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)



RN 921767-99-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

INDEX NAME)




RN 921768-00-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-[[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester
(CA INDEX NAME)




RN 921768-01-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester
(CA INDEX NAME)



RN 921768-02-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
 3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-
 , 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 921768-03-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
 3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-
 piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA
 INDEX NAME)




RN 921768-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 921768-05-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA
INDEX NAME)




RN 921768-06-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-, 1-ethyl
ester (CA INDEX NAME)




RN 921768-07-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl
ester (CA INDEX NAME)




RN 921768-08-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl
ester (CA INDEX NAME)




RN 921768-09-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX
NAME)




RN 921768-10-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-,
1-ethyl ester (CA INDEX NAME)




RN 921768-11-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)




RN 921768-12-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)



RN 921768-13-0 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
 3-[[4-(4-methyl-1-piperazinyl)-2-[[4-(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)




RN 921768-14-1 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
 3-[[4-(4-methyl-1-piperazinyl)-2-[[5-methyl-1H-pyrazol-3-yl]carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)




RN 921768-15-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
1-ethyl ester (CA INDEX NAME)




RN 921768-16-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)




RN 921768-17-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[2-[[[1-methyl-1-phenylethyl]amino]carbonyl]-3-[[2-[[1H-pyrrol-2-yl]carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-18-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[5-methyl-4-isoxazolyl]carbonyl]amino]benzoyl]amino]-5-[[[1-methyl-1-phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 921768-19-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[2-[[[1-methyl-1-phenylethyl]amino]carbonyl]-3-[[2-[[[2,3,4,5-tetrahydro-2H-pyran-4-yl]carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-20-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-21-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 921768-23-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 921768-25-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-
2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX
NAME)




RN 921768-27-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-
piperazinyl)benzoyl]amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 921768-29-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-
2-[[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester
(CA INDEX NAME)




RN 921768-31-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-
2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester
(CA INDEX NAME)




RN 921768-33-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 921768-35-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-ethyl ester (CA INDEX NAME)




RN 921768-36-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[[(1H-pyrrol-2-yl)carbonyl]amino]benzoyl]amino]-ethyl ester (CA INDEX NAME)




RN 921768-37-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-ethyl ester (CA INDEX NAME)




RN 921768-38-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[2-methyl-5-(2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-39-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[5-methyl-1H-pyrazol-3-yl]carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-40-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[2-furanylcarbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-41-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-5-
[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA
INDEX NAME)



RN 921768-42-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-
piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester
(CA INDEX NAME)



RN 921768-43-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,

5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-ethyl ester (CA INDEX NAME)




RN 921768-44-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-ethyl ester (CA INDEX NAME)




RN 921768-45-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-ethyl ester (CA INDEX NAME)




RN 921768-46-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921768-47-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[[[1-ethyl-3-methyl-1H-pyrazol-5-yl]carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 921769-00-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-nitrobenzoyl)amino]-, 1-ethyl ester (CA INDEX NAME)




RN 921769-02-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, 1-ethyl ester
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 921769-01-9


CMF C21 H22 N6 O7 S




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 921769-03-1 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 5-[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-nitrobenzoyl)amino]-,
 ethyl ester (CA INDEX NAME)



RN 921769-04-2 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-nitrobenzoyl)amino]-, ethyl ester (CA INDEX NAME)




RN 921769-05-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 5-[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921769-06-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-nitro-4-(1-pyrrolidinylmethyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921769-07-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-nitro-4-(1-piperidinylmethyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921769-08-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-morpholinylmethyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921769-09-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 921769-10-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(2-aminobenzoyl)amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 921769-11-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-5-[(2-aminobenzoyl)amino]-, ethyl ester (CA INDEX NAME)




RN 921769-12-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[1-(2-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 921769-13-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:916512 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:314984

TITLE: Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases

INVENTOR(S): Barberis, Claude; Carry, Jean-Christophe; Doerflinger, Gilles; Barbalat-Damour, Dominique; Clerc, Francois-Frederic; Minoux, Herve

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 138pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006092510	A1	20060908	WO 2006-FR480	20060303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2882751	A1	20060908	FR 2005-2199	20050304
FR 2882751	B1	20070914		
AU 2006219805	A1	20060908	AU 2006-219805	20060303
CA 2599270	A1	20060908	CA 2006-2599270	20060303
EP 1858898	A1	20071128	EP 2006-726018	20060303
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008531663	T	20080814	JP 2007-557544	20060303
US 20080146542	A1	20080619	US 2007-846669	20070829
MX 200710753	A	20071107	MX 2007-10753	20070903
KR 2007113214	A	20071128	KR 2007-720106	20070903
IN 2007KN03327	A	20080118	IN 2007-KN3327	20070907
CN 101151268	A	20080326	CN 2006-80010837	20070929
PRIORITY APPLN. INFO.:			FR 2005-2199	A 20050304
			WO 2006-FR480	W 20060303
OTHER SOURCE(S):		CASREACT 145:314984; MARPAT 145:314984		
GI				



- AB Title compds. I [R¹ = independently NHCOR², NHCONHR², NHCOOR²; R² = H, (un)substituted cyclo/alkyl, hetero/aryl, etc.; R³-R⁵ = independently H, (un)substituted alkyl, alkyl/aryl, alkyl/heteroaryl; or NR³R⁴ = (un)substituted heterocyclyl; etc.] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II. II inhibited Aurora 1, Aurora 2, CDK2 and Tie2 with IC₅₀ of 8 nM, 8 nM, 177 nM, and 117 nM, resp. I are useful for treating neoplasm, psoriasis, glaucoma, leukemias, inflammations, etc.
- IT 909252-57-9P, N-[5-(2-Phenylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-61-5P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-62-6P, N-[5-(2-Cyclohexylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-63-7P, N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-64-8P, N-[5-[(2-(2-Ethylphenyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-65-9P, N-[5-[(2-(2-Fluorophenyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-66-0P, 4-Methoxy-N-[5-[(2-(2-methylphenyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-67-1P, N-[5-[(2-(2-Methyl-2-phenylhydrazino)carbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(morpholin-4-yl)methyl]benzamide 909252-73-9P, 4-Bromo-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-75-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-78-4P, cis-4-[(3,5-Dimethylpiperazin-1-yl)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-79-5P 909252-89-7P 909252-90-0P 909252-91-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(piperazin-1-yl)methyl]benzamide 909252-92-2P 909252-93-3P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(3-methylpiperazin-1-yl)methyl]benzamide 909252-94-4P 909252-96-6P 909252-97-7P 909252-98-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-99-9P

909253-03-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(piperidin-1-yl)methyl]benzamide
 909253-04-9P 909253-05-0P,
 N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(pyrrolidin-1-yl)methyl]benzamide 909253-06-1P
 909253-07-2P, 4-[(Azetidin-1-yl)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
 909253-08-3P, 4-[(2-Dimethylaminoethyl)(methyl)amino]methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-09-4P 909253-10-7P
 909253-11-0P 909253-12-9P,
 N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-3-[(morpholin-4-yl)methyl]benzamide 909253-13-0P
 909253-16-3P, 4-[(2-Diethylaminoethyl)amino]methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
 909253-17-4P 909253-18-5P,
 4-[(Methyl(phenyl)amino)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
 909253-20-9P, 4-[(Diisopropylamino)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
 trifluoroacetate 909253-21-0P,
 N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909253-22-1P,
 4-Methoxy-N-[5-[(2-(pyridin-2-yl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-23-2P 909253-28-7P,
 N-(2-Methoxymethylpyrrolidin-1-yl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide
 909253-30-1P, N-[5-[(2-Benzyl-2-methylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 909253-32-3P, N-(Piperidin-1-yl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide
 909253-34-5P, N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-36-7P
 , N-[5-[(2-Ethyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-38-9P,
 N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-40-3P,
 N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-46-9P,
 N-[5-[(2-(4-Chlorophenyl)-2-cyclobutylmethylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 909253-52-7P, N-[5-[(2-Ethyl-2-(4-fluorophenyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 909253-55-0P, N-[5-[(2-(4-Fluorophenyl)-2-(2-methoxyethyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-58-3P,
 N-[5-[(2-Ethyl-2-(o-tolyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-59-4P,
 N-[5-[(2-Ethyl-2-(m-tolyl)hydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-60-7P,
 N-[5-[(2-(4-Fluorophenyl)-2-isobutylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-63-0P
 909253-67-1P, 6-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]nicotinamide
 909253-69-5P, N-[5-(Benzylidenehydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-71-0P
 , N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[2-(morpholin-4-yl)ethoxy]benzamide 909253-74-3P,
 4-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide

909253-75-4P 909253-76-5P 909253-77-6P,


N-[5-[[2-Ethyl-2-(p-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)


RN 909252-57-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-phenylhydrazide (CA INDEX NAME)




RN 909252-61-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-62-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-cyclohexylhydrazide (CA INDEX NAME)




RN 909252-63-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909252-64-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-ethylphenyl)hydrazide (CA INDEX NAME)




RN 909252-65-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-fluorophenyl)hydrazide (CA INDEX NAME)




RN 909252-66-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-methylphenyl)hydrazide (CA INDEX NAME)




RN 909252-67-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-73-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-bromobenzoyl)amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-75-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-78-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[[(3R,5S)-3,5-dimethyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 909252-79-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[[(3R,5S)-3,5-dimethyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide, rel- (CA INDEX NAME)


Relative stereochemistry.





PAGE 1-A




RN 909252-89-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-,
 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-90-0 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-,
 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909252-91-1 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-(1-piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide
 (CA INDEX NAME)




RN 909252-92-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-piperazinylmethyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909252-93-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-94-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A



RN 909252-96-6 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[(diethylamino)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide,
 trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 909252-95-5
 CMF C25 H28 N6 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 909252-97-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[(diethylamino)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909252-98-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-99-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Me


RN 909253-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-piperidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide
(CA INDEX NAME)




RN 909253-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-piperidinylmethyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-05-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide
(CA INDEX NAME)




RN 909253-06-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-07-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA
INDEX NAME)



RN 909253-08-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909253-09-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 909253-10-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-11-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-12-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide
 (CA INDEX NAME)




RN 909253-13-0 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-,
 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)



RN 909253-16-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-,
 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-17-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-,
 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)





RN 909253-18-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(methylphenylamino)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-20-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 909253-19-6

CMF C27 H32 N6 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 909253-21-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-methoxybenzoyl]amino]-,
2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-22-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-pyridinyl)hydrazide (CA INDEX NAME)




RN 909253-23-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-28-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[2-(methoxymethyl)-1-pyrrolidinyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 909253-30-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-32-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-1-piperidinyl- (CA INDEX NAME)




RN 909253-34-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-36-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-38-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-40-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide
(CA INDEX NAME)




RN 909253-46-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide (CA INDEX NAME)




RN 909253-52-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-fluorophenyl)hydrazide (CA INDEX NAME)




RN 909253-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-fluorophenyl)-2-(2-methoxyethyl)hydrazide (CA INDEX NAME)




RN 909253-58-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-(2-methylphenyl)hydrazide (CA INDEX NAME)




RN 909253-59-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-(3-methylphenyl)hydrazide (CA INDEX NAME)




RN 909253-60-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(4-fluorophenyl)-2-(2-methylpropyl)hydrazide (CA INDEX NAME)




RN 909253-63-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(3-bromophenyl)-2-ethylhydrazide (CA INDEX NAME)



RN 909253-67-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-pyridinyl]carbonyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)]




RN 909253-71-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[[4-(2-(4-morpholinyl)ethoxy)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)]



RN 909253-74-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)]



RN 909253-75-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
 2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide, 2,2,2-trifluoroacetate
 (1:1) (CA INDEX NAME)

CM 1

CRN 909253-46-9
 CMF C29 H32 Cl N7 O2 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 909253-76-5 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
 2-ethyl-2-(4-fluorophenyl)hydrazide, 2,2,2-trifluoroacetate (1:1) (CA
 INDEX NAME)

CM 1

CRN 909253-52-7
 CMF C26 H28 F N7 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 909253-77-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-(4-methylphenyl)hydrazide (CA INDEX NAME)



IT 909252-58-0P, 1-(1-Ethoxyethyl)-3-(4-methoxybenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid 909252-59-1P
909252-60-4P, Ethyl 1-(1-ethoxyethyl)-3-(4-methoxybenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylate 909252-68-2P
909252-69-3P, tert-Butyl 3-amino-5-[(2-methyl-2-phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-70-6P, N'-Methyl-N'-phenyl-3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylic hydrazide 909252-71-7P, Ethyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate 909252-74-0P, tert-Butyl 3-(4-bromobenzoylamino)-5-[(2-methyl-2-phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-76-2P, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylate 909252-80-8P, tert-Butyl 3-(4-chloromethylbenzoylamino)-5-[(2-methyl-2-phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-81-9P 909252-82-0P 909253-00-5E, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[3-[(4-methylpiperazin-1-yl)methyl]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylate 909253-01-6P 909253-14-1P, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[3-[(morpholin-4-yl)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-carboxylate

909253-15-2P 909253-24-3P, Ethyl

1-(1-ethoxyethyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylate 909253-25-4P 909253-29-8P

909253-31-2P 909253-33-4P 909253-35-6P

909253-37-8P 909253-43-6P 909253-48-1P

909253-53-8P 909253-69-6P,


N-[5-(Hydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-72-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)


RN 909252-58-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(4-methoxybenzoyl)amino]- (CA INDEX NAME)




RN 909252-59-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(4-methoxybenzoyl)amino]-, 2-phenylhydrazide (CA INDEX NAME)




RN 909252-60-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(4-methoxybenzoyl)amino]-, ethyl ester (CA INDEX NAME)




RN 909252-68-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[[4-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)




RN 909252-69-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)




RN 909252-70-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-71-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, ethyl ester (CA INDEX NAME)




RN 909252-74-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-bromobenzoyl)amino]-, 1-(1,1-dimethylethyl) ester,
5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)




RN 909252-76-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX
NAME)




RN 909252-80-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-(chloromethyl)benzoyl)amino]-, 1-(1,1-dimethylethyl) ester,
5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)




RN 909252-81-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-(chloromethyl)benzoyl)amino]-, 1-(1,1-dimethylethyl) ester,
5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)




RN 909252-82-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-,
1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA
INDEX NAME)




RN 909253-00-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX
NAME)



RN 909253-01-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA
INDEX NAME)



Me


RN 909253-14-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester,
5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)




RN 909253-15-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester,
5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)




RN 909253-24-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl
ester (CA INDEX NAME)




RN 909253-25-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-29-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
1-(1-ethoxyethyl)-N-[2-(methoxymethyl)-1-pyrrolidinyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 909253-31-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-methyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-33-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-1-
piperidiny- (CA INDEX NAME)




RN 909253-35-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-37-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-phenylhydrazide (CA INDEX NAME)



RN 909253-43-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)





RN 909253-72-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-[2-(4-morpholinyl)ethoxy]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)




IT 909253-39-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of
protein kinases)

RN 909253-39-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




IT 909253-70-9P, Ethyl 3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-1H-
thieno[2,3-c]pyrazole-5-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of
protein kinases)

RN 909253-70-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX
NAME)



IT 909252-87-5P, N'-(4-Chlorophenyl)-N'-methyl-3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylic hydrazide
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)
 RN 909252-87-5 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-,
 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2006:708185 CAPLUS Full-text
 DOCUMENT NUMBER: 145:167237
 TITLE: Preparation of heterocyclo-fused pyrazoles as protein kinase inhibitors.
 INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala', Valeria; D' Anello, Matteo
 PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
US 20060160874	A1	20060720	US 2005-37986	20050118
PRIORITY APPLN. INFO.:			US 2005-37986	20050118
OTHER SOURCE(S):	MARPAT	145:167237		

GI




AB Title compds. [1-X NR', O, S, SO, SO2; R, R1 = H, (substituted) R', COR', CO2R', CONHR', SO2R', etc.; R2 = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl; R' = R', CH2OR', OR'], were prepared Thus, Me 3-[[4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate (preparation from Me 5-bromo-4-nitrothiophene-2-carboxylate and morpholin-4-ylbenzoic acid given) inhibited Aurora-1 kinase with IC50 <100 nM.

IT 648412-09-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclo-fused pyrazoles as protein kinase inhibitors)



RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl)amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)



L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:510459 CAPLUS Full-text
 DOCUMENT NUMBER: 145:8163
 TITLE: Substituted 1H-thieno[2,3-c]pyrazoles, their
 preparation, compositions containing them and their
 use as inhibitors of protein kinases for treating
 cancer
 INVENTOR(S): Carry, Jean-Christophe; Doerflinger, Gilles; Bigot,
 Antony; Barbalat-Damour, Dominique; Clerc, Francois
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056697	A1	20060601	WO 2005-FR2933	20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2878442	A1	20060602	FR 2004-12644	20041129
FR 2878442	B1	20081024		
EP 1824859	A1	20070829	EP 2005-822880	20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008521781	T	20080626	JP 2007-542047	20051125
US 20080058402	A1	20080306	US 2007-752612	20070523
PRIORITY APPLN. INFO.:			FR 2004-12644	A 20041129
			WO 2005-FR2933	W 20051125
OTHER SOURCE(S):		CASREACT 145:8163; MARPAT 145:8163		
GI				




- AB Title compds. I [R1 = independently R2, NHCOR2, CH:CH-R2, etc.; R2 = heteroaryl/aryl/heterocyclo/cyclo/alkyl, etc.; R3 = alkyl, alkyl/aryl, alkyl/heteroaryl; with the proviso that when R3 = alkyl, than R1 is not heteroaryl or CH:CH-R2, where R2 = heteroaryl; their racemates, enantiomers and diastereomers, and their pharmaceutical addition salts with mineral and organic acids or mineral and organic bases] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II•HCl. II inhibited Aurora 2, CDK2 and Tie2 with IC50 of < 50 nM, < 500 nM and < 500 nM, resp.
- IT 888485-00-5P, 5-[(N-Phenoxyamino)carbonyl]-3-[[thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole hydrochloride
888485-03-3P, 5-[(N-Phenoxyamino)carbonyl]-3-[[thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1H-thieno[2,3-c]pyrazoles as inhibitors of protein kinases and their use for treating cancer)

RN 888485-00-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-phenoxy-3-[(2-thienylcarbonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 888485-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-phenoxy-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




IT 936633-22-8P, Ethyl 1-(1-ethoxyethyl)-3-[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole-5-carboxylate
888485-01-6P, 1-(1-Ethoxyethyl)-5-[(N-phenoxyamino)carbonyl]-3-[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole
888485-02-7P, 1-(1-Ethoxyethyl)-3-[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1H-thieno[2,3-c]pyrazoles as inhibitors of protein kinases and their use for treating cancer)


RN 836633-22-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 888485-01-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
1-(1-ethoxyethyl)-N-phenoxy-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 888485-02-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1104610 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:249062

TITLE: Synthesis, reactions and antimicrobial activity of
2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-
carbonitrile

AUTHOR(S): Abdel-Mohsen, Shawkat A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Assiut
University, Assiut, 71516, Egypt

SOURCE: Bulletin of the Korean Chemical Society (2005), 26(5),
719-728


CODEN: BKCSDE; ISSN: 0253-2964

PUBLISHER: Korean Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:249062



AB A novel 2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-carbonitrile (I) was obtained by the reaction of 2-[2-bromo-1-(8-hydroxyquinolin-5-yl)-ethylidene]-malononitrile with p-toluidine. The new synthon I could be annulated to the corresponding pyrrolo[2,3-d]pyrimidines, triazolo[1,5-c]pyrrolo[3,2-e]pyrimidines, pyrrolo[2,3-c]pyrazoles, pyrrolo[1,2-a]pyrrolo[3,2-e]pyrimidine and imidazo[1,2-c]pyrrolo[3,2-e]pyrimidine via the reactions with some reagents such as acetic anhydride, formamide, tri-Et orthoformate, hydrazine hydrate, hydroxylamine, ethylenediamine, carbon disulfide and phosphorus oxychloride. Chemical and spectroscopic data for the structures of these compds. were presented. The antifungal and antibacterial activity of the newly synthesized compds. were evaluated.


IT 906450-63-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-63-3 CAPLUS

CN 8-Quinolinol, 5-[3-amino-1,6-dihydro-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-4-yl]- (CA INDEX NAME)




IT 906450-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-67-7 CAPLUS

CN Thiourea, N-[1,6-dihydro-4-(8-hydroxy-5-quinolinyl)-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-3-yl]-N'-phenyl- (CA INDEX NAME)




IT 906450-64-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-64-4 CAPLUS

CN 8-Quinolinol, 5-[1,6-dihydro-6-(4-methylphenyl)-3-[(phenylmethylene)amino]pyrrolo[2,3-c]pyrazol-4-yl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823564 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:229842

TITLE: Preparation of thieno[2,3-c]pyrazole derivatives as protein kinase inhibitors

INVENTOR(S): Fancelli, Daniele; Bindi, Simona; Varasi, Mario; Vianello, Paola; Vioglio, Sergio; Tesei, Dania

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074922	A1	20050818	WO 2005-EP1021	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

AU 2005210114	A1	20050818	AU 2005-210114	20050202
CA 2555262	A1	20050818	CA 2005-2555262	20050202
EP 1711177	A1	20061018	EP 2005-701307	20050202
EP 1711177	B1	20080528		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1946395	A	20070411	CN 2005-80005922	20050202
BR 2005007375	A	20070710	BR 2005-7375	20050202
JP 2007520513	T	20070726	JP 2006-551790	20050202
AT 396724	T	20080615	AT 2005-701307	20050202
ES 2307144	T3	20081116	ES 2005-701307	20050202
US 20050187209	A1	20050825	US 2005-50360	20050203
IN 2006DN04402	A	20070810	IN 2006-DN4402	20060731
MX 2006PA08787	A	20070119	MX 2006-PA8787	20060802
NO 2006003768	A	20061102	NO 2006-3768	20060823
KR 2006124734	A	20061205	KR 2006-717754	20060901

PRIORITY APPLN. INFO.:	US 2004-541452P	P	20040203
	WO 2005-EP1021	W	20050202

OTHER SOURCE(S): CASREACT 143:229842; MARPAT 143:229842
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted aryl or heteroaryl; R1 and R2 independently = H, alkyl, CONH2, etc. or together may form cycloalkyl ring with provisions; R3 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amination of 1-(ethoxycarbonyl)-3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[2,3- c]pyrazole-5-carboxylic acid hydrochloride (preparation given) with cumylamine and subsequent deprotection. The inhibitory activity of I towards Aurora-2 kinase was evaluated utilizing a scintillation assay and it was revealed that selected compds. of the invention displayed IC50 values below 20 nM. I as protein kinase inhibitor should prove useful in the treatment of cancer. Pharmaceutical compds. comprising I are disclosed.

IT 648412-09-3P 836633-13-7P 862555-81-5P
 862555-87-1P 862555-94-0P 862555-99-5P
 862556-05-6P 862556-11-4P 862556-16-9P
 862556-21-6P 862556-27-2P 862556-33-0P
 862556-38-5P 862556-43-2P 862556-47-6P
 862556-52-3P 862556-57-8P 862556-67-0P
 862556-71-6P 862556-75-0P 862556-78-3P
 862556-81-8P 862556-84-1P 862556-87-4P
 862556-90-9P 862556-93-2P 862556-96-5P
 862556-99-8P 862557-02-6P 862557-05-9P
 862557-08-2P 862557-11-7P 862557-14-0P
 862557-17-3P 862557-20-6P 862557-23-1P

862557-26-6P 862557-30-0P 862557-32-2P
 862557-34-4P 862557-37-7P 862557-39-9P
 862557-41-3P 862557-43-5P 862557-45-7P
 862557-47-9P 862557-49-1P 862557-51-5P
 862557-53-7P 862557-54-8P 862557-55-9P
 862557-58-2P 862557-61-7P 862557-64-0P
 862557-67-3P 862557-69-5P 862557-71-9P
 862557-73-1P 862557-75-3P 862557-77-5P
 862557-79-7P 862557-81-1P 862557-83-3P
 862557-85-5P 862557-86-6P 862557-88-8P
 862557-90-2P 862557-92-4P 862557-94-6P
 862557-95-7P 862557-96-8P 862557-98-0P
 862558-00-7P 862558-01-8P 862558-03-0P
 862558-05-2P 862558-07-4P 862558-09-6P
 862558-11-0P 862558-13-2P 862558-15-4P
 862558-17-6P 862558-19-8P 862558-21-2P
 862558-23-4P 862558-27-8P 862558-30-3P
 862558-32-5P 862558-34-7P 862558-36-5P
 862558-38-1P 862558-40-5P 862558-42-7P
 862558-44-9P 862558-46-1P 862558-48-3P
 862558-50-7P 862558-52-9P 862558-54-1P
 862558-56-3P 862558-58-5P 862558-60-9P
 862558-63-2P 862558-65-4P 862558-67-6P
 862558-69-8P 862558-71-2P 862558-73-4P
 862558-75-6P 862558-77-8P 862558-79-0P
 862558-81-4P 862558-83-6P 862558-85-8P
 862558-87-0P 862558-89-2P 862558-91-6P
 862558-93-8P 862558-95-0P 862558-97-2P
 862559-00-0P 862559-01-1P
 862559-02-2P 862559-03-3P 862559-04-4P
 862559-05-5P 862559-06-6P 862559-07-7P
 862559-08-8P 862559-09-9P 862559-10-2P
 862559-11-3P 862559-12-4P 862559-13-5P
 862559-15-7P 862559-17-9P 862559-19-1P
 862559-20-4P 862559-21-5P 862559-23-7P
 862559-24-8P 862559-26-0P 862559-28-2P
 862559-29-3P 862559-30-6P 862559-32-8P
 862559-34-0P 862559-36-2P 862559-38-4P
 862559-40-8P 862559-42-0P 862559-44-2P
 862559-46-4P 862559-48-6P 862559-50-0P
 862559-52-2P 862559-53-3P 862559-54-4P
 862559-55-5P 862559-57-7P 862559-59-9P
 862559-60-2P 862559-61-3P 862564-01-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)

RN 648412-09-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]-4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862555-81-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]-4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862555-87-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862555-94-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 862555-99-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 862556-05-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-
pyrrolidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 862556-11-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-16-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-21-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862556-27-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-33-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-38-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-43-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,


3-[(4-fluorobenzoyl)amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-47-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1-ethyl-1-phenylpropyl)-3-[(4-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 862556-52-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 862556-57-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[(2-thienylcarbonyl)amino]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 862556-67-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)


NAME)

Absolute stereochemistry.



RN 862556-71-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-phenylcyclopropyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 862556-75-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]-
(CA INDEX NAME)


Absolute stereochemistry.




RN 862556-78-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1R)-1-phenylpropyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 862556-81-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-
 (CA INDEX NAME)




RN 862556-84-1 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-N-(1-phenylcyclopropyl)- (CA
 INDEX NAME)



RN 862556-87-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[(2-furanylcarbonyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-90-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[(2-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862556-93-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-
piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862556-96-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)-
(CA INDEX NAME)




RN 862556-99-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)



RN 862557-02-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-N-(1-
phenylcyclopropyl)- (CA INDEX NAME)



RN 862557-05-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-piperazinyl)benzoyl]amino]-


(CA INDEX NAME)



RN 862557-08-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 862557-11-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-
phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862557-14-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-
pyrrolidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862557-17-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862557-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA
INDEX NAME)




RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA
INDEX NAME)




RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA
INDEX NAME)




RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA
INDEX NAME)



RN 862557-34-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[[[(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-
phenylethyl)- (CA INDEX NAME)



RN 862557-37-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]benzoyl]amino]-N-(1-methyl-1-

phenylethyl)- (CA INDEX NAME)




RN 862557-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-41-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-43-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-45-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[[[5-[(1-methyl-1-
phenylethyl)amino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-
yl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX

NAME)




RN 862557-47-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-{(1-methyl-1-phenylethyl)benzoyl}amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-49-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperazinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-51-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1H-imidazol-1-ylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862557-53-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(3-thiazolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

(CA INDEX NAME)




RN 862557-54-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-55-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-58-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-61-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA
INDEX NAME)




RN 862557-64-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinemethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-67-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinemethyl)benzoyl]amino]-N-[1-(3-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-69-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinemethyl)benzoyl]amino]-N-[1-(4-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-71-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[[4-(1,1-dimethylethyl)-1-piperazinyl]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-73-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-75-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-77-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(2-phenylacetyl)amino]- (CA INDEX NAME)




RN 862557-79-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-(dimethylamino)methyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-85-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(methyl(1-methylethyl)amino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)




RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-90-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(aminomethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-94-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-95-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-96-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-
pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-98-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-00-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-01-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-
piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-03-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-
methylethyl]- (CA INDEX NAME)




RN 862558-05-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(3-methoxyphenyl)-1-
methylethyl]- (CA INDEX NAME)




RN 862558-07-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(4-methoxyphenyl)-1-
methylethyl]- (CA INDEX NAME)




RN 862558-09-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-11-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-13-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-
morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-15-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)



RN 862558-17-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

Me

PAGE 1-B

RN 862558-19-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

Me

PAGE 1-B


RN 862558-21-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)



RN 862558-23-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-
piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

Me

PAGE 1-B


RN 862558-27-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyloxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-30-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyloxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-32-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-34-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-36-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)



RN 862558-38-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-
piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)



RN 862558-40-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-

methylethyl]- (CA INDEX NAME)




RN 862558-42-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-46-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-((hexahydro-1H-azepin-1-yl)methyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-52-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(1H-pyrazol-1-ylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-54-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-56-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-58-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(2-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-60-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1-methyl-1-phenylethyl)-3-[[3-(4-morpholinyl)benzoyl]amino]]- (CA INDEX NAME)




RN 862558-63-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(dimethylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-65-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(3-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-67-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(3-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-69-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(1-methyl-1H-pyrrol-3-yl)carbonyl]amino]-
(CA INDEX NAME)




RN 862558-71-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]-
(CA INDEX NAME)




RN 862558-73-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-
(CA INDEX NAME)




RN 862558-75-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(2-pyridinylcarbonyl)amino]- (CA INDEX
NAME)




RN 862558-77-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(3-pyridinylcarbonyl)amino]- (CA INDEX
NAME)




RN 862558-79-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(4-pyridinylcarbonyl)amino]- (CA INDEX
NAME)




RN 862558-81-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-chlorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-83-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(4-phenoxybenzoyl)amino]- (CA INDEX NAME)




RN 862558-85-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862558-87-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862558-89-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-91-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-93-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-95-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[2-(thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-97-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-phenylcyclopentyl)-3-[[2-(thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-99-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA
INDEX NAME)



RN 862559-00-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA
INDEX NAME)



RN 862559-01-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[[4-(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862559-02-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)



RN 862559-03-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-
(CA INDEX NAME)



RN 862559-04-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 862559-05-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX
NAME)



RN 862559-06-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 862559-07-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX
NAME)




RN 862559-08-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-09-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-fluorobenzoyl)amino]- (CA
INDEX NAME)




RN 862559-10-2 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[(4-methoxybenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 862559-11-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-(1-phenylcyclopropyl)-3-[[4-(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)




RN 862559-12-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-(1-methyl-1-phenylethyl)-3-[[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]amino]- (CA INDEX NAME)




RN 862559-13-5 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-[(1S)-1-methyl-2-(4-morpholinyl)-1-phenylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862559-15-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-methyl-1-(4-pyridinyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862559-17-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862559-19-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)



RN 862559-20-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-

piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-21-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-
piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-23-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(methylsulfonyl)benzoyl]amino]- (CA
INDEX NAME)




RN 862559-24-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1,1-dioxido-4-thiomorpholinyl)benzoyl]amino]-N-(1-methyl-1-
phenylethyl)- (CA INDEX NAME)




RN 862559-26-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-[[4-(4-
morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-28-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 862559-29-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-methyl-1-[3-(methylsulfonyl)phenylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-
(CA INDEX NAME)




RN 862559-36-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[2-thienylcarbonyl]amino]- (CA
INDEX NAME)




RN 862559-38-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[2-thienylcarbonyl]amino]- (CA
INDEX NAME)




RN 862559-40-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[2-thienylcarbonyl]amino]- (CA
INDEX NAME)




RN 862559-42-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA
INDEX NAME)




RN 862559-44-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA
INDEX NAME)




RN 862559-46-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA
INDEX NAME)




RN 862559-48-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA
INDEX NAME)




RN 862559-50-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(2-furanylcarbonyl)amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA
INDEX NAME)




RN 862559-52-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[1-(1-methyl-1H-pyrazol-5-
yl)carbonyl]amino]- (CA INDEX NAME)




RN 862559-53-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[1-(1-methyl-1H-pyrazol-5-
yl)carbonyl]amino]- (CA INDEX NAME)



RN 862559-54-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[1-(1-methyl-1H-pyrazol-5-
yl)carbonyl]amino]- (CA INDEX NAME)



RN 862559-55-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 862559-57-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX
NAME)

Absolute stereochemistry.




RN 862559-59-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862559-60-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(3-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862559-61-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(2-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862564-01-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

Me

PAGE 1-B


IT 1044679-82-5P 1044679-84-6P 1044679-86-8P
 1044679-88-0P 1044679-91-5P 1044679-93-7P
 1044679-94-8P 1044679-96-0P 1044679-99-3P
 1044680-01-4P 1044680-02-5P 1044680-04-7P
 1044680-07-0P 1044680-09-2P 1044680-10-5P
 1044680-12-7P 1044680-15-0P 1044680-17-2P
 1044680-20-7P 1044680-24-1P 1044680-25-2P
 1044680-27-4P 1044680-28-5P 1044680-32-1P
 1044680-34-3P 1044680-35-4P 1044680-40-1P
 1044680-42-3P 1044680-45-6P 1044680-47-8P
 1044680-48-9P 1044680-50-3P 1044680-53-6P
 1044680-55-8P 1044680-57-0P 1044680-58-1P
 1044680-61-6P 1044680-64-9P 1044680-65-0P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)
 RN 1044679-83-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1044679-84-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1044679-86-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 3-[(4-fluorobenzoyl)amino]-5-[[[(1R)-1-(4-
 fluorophenyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1044679-88-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-3-[(2-
thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1044679-91-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(2-furanylcarbonyl)amino]-5-[[[(1-phenylcyclopropyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1044679-93-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1044679-94-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044679-96-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1044679-99-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-furanylcarbonyl)amino]-, 5-[(1,1-dimethylethyl) 1-ethyl ester (CA
INDEX NAME)




RN 1044680-01-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,

3-[(1-methyl-1H-pyrrol-2-yl)carbonylamino]-, 1-ethyl ester (CA INDEX NAME)




RN 1044680-02-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1044680-04-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1044680-07-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-1-phenyl-2-(1-
pyrrolidinyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1044680-09-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1044680-10-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1R)-1-phenylpropyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1044680-12-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-5-[(1-phenylcyclopropyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1044680-15-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(4-fluorobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA
INDEX NAME)




RN 1044680-17-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044680-20-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-furanylcarbonyl)amino]-, 1-ethyl ester (CA INDEX NAME)




RN 1044680-24-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044680-25-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[1-(phenylcyclopropyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)



RN 1044680-27-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[(4-fluorobenzoyl)amino]-,
ethyl ester (CA INDEX NAME)



RN 1044680-28-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1044680-32-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1044680-34-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl)
1-ethyl ester (CA INDEX NAME)




RN 1044680-35-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[2-thienylcarbonyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA
INDEX NAME)




RN 1044680-40-1 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
 3-[(4-fluorobenzoyl)amino]-, 1-ethyl ester (CA INDEX NAME)



RN 1044680-42-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1044680-45-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 1044680-47-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 3-[(4-fluorobenzoyl)amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
 ethyl ester (CA INDEX NAME)




RN 1044680-48-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[1-(1-phenylcyclopentyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)



RN 1044680-50-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)



RN 1044680-53-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-fluorobenzoyl)amino]-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]-,
ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1044680-55-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[(1-phenylcyclopropyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1044680-57-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(2-furanylcarbonyl)amino]-5-[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1044680-58-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044680-61-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1044680-64-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[1-(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-, 5-(1,1-dimethylethyl)
1-ethyl ester (CA INDEX NAME)



RN 1044680-65-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-thienylcarbonyl)amino]-, 1-ethyl ester (CA INDEX NAME)




IT 1044680-19-4P 1044680-39-8P

RL: PRPH (Prophetic); SPN (Synthetic preparation); PREP (Preparation)
(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)


RN 1044680-19-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1044680-39-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1056901-68-8 1056901-69-9 1056901-72-4
1056901-92-8 1056901-93-9 1056902-05-6
1056902-08-9 1056902-09-0 1056902-10-3
1056902-13-6 1056902-17-0 1056902-18-1
1056902-24-9 1056902-36-3 1056902-37-4
1056902-38-5 1056902-39-6 1056902-40-9
1056902-41-0 1056902-42-1 1056902-44-3
1056902-45-4 1056902-46-5 1056902-47-6
1056902-48-7 1056902-51-2 1056902-52-3
1056902-53-4 1056902-54-5 1056902-62-5
1056902-75-0 1056902-85-2 1056902-87-4
1056902-88-5 1056902-93-2 1056903-06-0
1056903-07-1 1056903-08-2 1056903-09-3
1056903-10-6 1056903-11-7 1056903-12-8
1056903-13-9 1056903-14-0 1056903-16-2
1056903-18-4 1056903-19-5 1056903-20-6
1056903-21-9 1056903-22-0 1056903-23-1
1056903-24-2 1056903-25-3 1056903-26-4
1056903-27-5 1056903-28-6 1056903-29-7
1056903-30-0 1056903-31-1 1056903-32-2
1056903-33-3 1056903-34-4 1056903-35-5
1056903-36-6 1056903-37-7 1056903-38-8
1056903-39-9 1056903-40-2 1056903-41-3
1056903-44-6 1056903-45-7 1056903-46-8
1056903-51-3


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)

RN 1056901-68-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-amino-5-[(1-phenylcyclopropyl)amino]carbonyl-, ethyl ester (CA INDEX
NAME)




RN 1056901-69-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(3-fluorophenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056901-72-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056901-92-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(4-fluorophenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056901-93-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056902-05-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(3-methoxyphenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056902-08-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(4-methoxyphenyl)-1-methylethyl]-
(CA INDEX NAME)




RN 1056902-09-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-methoxybenzoyl)amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056902-10-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(3-methoxybenzoyl)amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056902-13-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(2-methoxybenzoyl)amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056902-17-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[3-(4-
morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-18-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(dimethylamino)benzoyl]amino]-5-[[[(1-methyl-1-
phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1056902-24-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[3-(3-furanylcarbonyl)amino]-5-[[1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056902-36-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-methyl-1-phenylethyl)amino]carbonyl]-3-[(3-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1056902-37-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-methyl-1-phenylethyl)amino]carbonyl]-3-[[1-methyl-1H-pyrrol-3-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-38-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-methyl-1-phenylethyl)amino]carbonyl]-3-[[1-methyl-1H-pyrazol-3-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-39-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-40-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-pyridinylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-41-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(3-pyridinylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-42-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(4-pyridinylcarbonyl)amino]-
, ethyl ester (CA INDEX NAME)




RN 1056902-44-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-chlorobenzoyl)amino]-5-[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056902-45-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(4-phenoxybenzoyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1056902-46-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-47-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-48-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-51-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056902-52-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1056902-53-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(1-phenylcyclopentyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1056902-54-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)



RN 1056902-62-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-
thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)



RN 1056902-75-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1S)-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-3-[[4-(
trifluoromethoxy)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1056902-85-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-
methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1056902-87-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-5-[[[1-methyl-1-
phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 1056902-88-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1056902-93-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1056903-06-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1056903-07-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[1-phenylcyclopentyl]amino]carbonyl-, ethyl ester (CA INDEX NAME)




RN 1056903-08-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(3-chlorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(3-chlorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-fluorobenzoyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-10-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-methoxybenzoyl)amino]-5-[(1-phenylcyclopropyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)




RN 1056903-11-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[(1-phenylcyclopropyl)amino]carbonyl]-3-[[4-(trifluoromethoxy)benzoyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1056903-12-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1056903-13-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1S)-1-methyl-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1056903-14-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-pyridinyl)ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-16-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-18-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-19-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-21-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(methylsulfonyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-22-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[[4-(1,1-dioxido-4-thiomorpholinyl)benzoyl]amino]-5-[[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1056903-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-24-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1056903-25-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-methyl-1-[3-(methylsulfonyl)phenyl]ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-26-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-27-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-29-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-31-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-33-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-35-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-36-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(2-furanylcarbonyl)amino]-5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1056903-37-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[1-(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1056903-38-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[1-(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1056903-39-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[1-(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1056903-40-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1056903-41-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[[(1S)-1-phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 1056903-44-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-(benzoylamino)-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester
(CA INDEX NAME)




RN 1056903-45-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 3-[(3-fluorobenzoyl)amino]-5-[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-,
 ethyl ester (CA INDEX NAME)



RN 1056903-46-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 3-[(2-fluorobenzoyl)amino]-5-[[1-(1-methyl-1-phenylethyl)amino]carbonyl]-,
 ethyl ester (CA INDEX NAME)



RN 1056903-91-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




IT 556235-19-6P, tert-Butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-
 carboxylate 862559-62-4P 862559-63-5P
 862559-65-7P 862559-67-9P 862559-69-1P
 862559-71-5P 862559-73-7P 862559-75-9P
 862559-77-1P 862559-80-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)


RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862559-62-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)




RN 862559-63-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-morpholinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)



RN 862559-65-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-morpholinyl)benzoyl]amino]-, 1-ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 862559-67-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[4-(1-methyl-1-phenylethyl)amino]benzoyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 862559-69-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-[4-(4-methyl-1-piperazinyl)benzoyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862559-71-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)



RN 862559-73-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, hydrochloride (1:1) (CA
INDEX NAME)



● HCl


RN 862559-75-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(chloromethyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester
(CA INDEX NAME)




RN 862559-77-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(chloromethyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)




RN 862559-80-6 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
 3-[[4-(chloromethyl)benzoyl]amino]-5-[[[(1-methyl-1-
 phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:99176 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:198080
 TITLE: Preparation of substituted thieno[2,3-c]pyrazoles and
 their use as medicinal products for cancer and
 neurodegenerative diseases
 INVENTOR(S): Bigot, Antony; Clerc, Francois; Doerflinger, Gilles;
 Mignani, Serge; Minoux, Herve
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050026984	A1	20050203	US 2004-900549	20040728
PRIORITY APPLN. INFO.:			FR 2003-9284	A 20030729
			US 2003-500614P	P 20030905
OTHER SOURCE(S):			CASREACT 142:198080; MARPAT 142:198080	
GI				



AB The present invention relates in particular to novel chemical compds.,
 particularly novel substituted thieno[2,3-c]pyrazoles I [R1 = XY; X = ; Y =
 (un)substituted; R2 = XY, ; R = H, alkyl; n = 0 - 2; a = 1, 2; all above are
 optionally substituted with alkyl, aryl, amino or alkoxy; with the proviso

that when R2 = R1, then X ≠ NHCO, NHSO2], to the compns. containing them and to their use as medicinal products for treating cancers and also neurodegenerative diseases. Thus, 3-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid N-benzyl-N-methylamide [I; R1 = Ph, R2 = CONMeCH2Ph] was prepared from 1-benzyl-5-chloro-3-phenylpyrazole-4-carboxaldehyde via cyclocondensation with HSCH2CO2Et, chlorination with SOCl2 and amidation with PhCH2NHMe. The protein kinase inhibitory activity of I was tested against FAK, KDR, Aurora 2, Src and Tie2 (Ki = 100 - 5000 nM).

IT 836633-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and N-deprotection of; preparation of thieno[2,3-c]pyrazole derivs.

for use in treatment of cancer and neurodegenerative diseases)

RN 836633-20-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

1-(1-ethoxyethyl)-N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]-
(CA INDEX NAME)



IT 836633-22-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amidation of, with cumylamine; preparation of thieno[2,3-c]pyrazole derivs. for use in treatment of cancer and neurodegenerative diseases)

RN 836633-22-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

1-(1-ethoxyethyl)-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)




IT 836633-13-7P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thieno[2,3-c]pyrazole derivs. for use in treatment of cancer and neurodegenerative diseases)

RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



L3 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1001062 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:113983

TITLE: Mononuclear heterocyclic rearrangement: Synthesis of [5:5] bicyclic [c]-fused 3-aminopyrazoles via the N-N bond formation strategy

AUTHOR(S): Berry, David A.; Chien, Tun-Cheng; Townsend, Leroy B.

CORPORATE SOURCE: Department of Medicinal Chemistry, College of Pharmacy, The University of Michigan, Ann Arbor, MI, 48109-1065, USA

SOURCE: Heterocycles (2004), 63(11), 2475-2494

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:113983

AB The formation of [5:5] bicyclic heterocyclic ring systems containing [c]pyrazoles, i.e. imidazo[4,5-c]pyrazole, pyrazolo[3,4-c]pyrazole, pyrrolo[2,3-c]pyrazole, and pyrazolo[3,4-d][1,2,3]triazole, was accomplished by mononuclear heterocyclic rearrangement (MHR). The core pyrazole ring was formed based on a N-N bond formation strategy. The ring transformation of 5-substituted 3-(2-aminoaryl)-1,2,4-oxadiazoles, under thermal conditions to the corresponding [5:5] bicyclic [c]-fused 3-aminopyrazole ring systems was promoted by sodium hydride in DMF or DMSO. The ring transformation by MHR has provided a practical and general synthetic method for the derivs. of 3-aminoimidazo[4,5-c]pyrazole, 3-aminopyrrolo[2,3-c]pyrazole, and 6-aminopyrazolo[3,4-d][1,2,3]triazole.

IT 821004-47-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-[cyano(pyrrolo[2,3-c]pyrazolyl)]benzamide using

[amino(iminomethyl)pyrrolocarboxamide as synthetic intermediate)

RN 821004-47-1 CAPLUS

CN Benzamide, N-[5-cyano-1,6-dihydro-6-(phenylmethyl)pyrrolo[2,3-c]pyrazol-3-yl]-4-nitro- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:414631 CAPLUS Full-text

DOCUMENT NUMBER: 140:423660

TITLE: Preparation of thieno[3,2-c]pyridines and related

compounds as antiinflammatory agents

INVENTOR(S): Burkitt, Simon A.; Cardozo, Mario G.; Cushing, Timothy

D.; DeGraffenreid, Michael R.; Farthing, Christopher

N.; Hao, Xiaolin; Jaen, Juan C.; Jiao, Xian Yun;

Kopecky, David J.; Labelle, Marc; Lively, Sarah E.;

McMinn, Dustin L.; Rasmussen, Sven P.; Shin,

Youngsook; Smith, Andrew; Smith, Marie-Louise

Tularik Inc., USA

PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 70 pp.

SOURCE: CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040097485	A1	20040520	US 2003-666857	20030919
US 7199119	B2	20070403		
CA 2502429	A1	20040521	CA 2003-2502429	20030919
WO 2004041285	A1	20040521	WO 2003-US29143	20030919
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003270701	A1	20040607	AU 2003-270701	20030919
EP 1556053	A1	20050727	EP 2003-752410	20030919
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006512313	T	20060413	JP 2004-549954	20030919
US 20070155777	A1	20070705	US 2007-709895	20070221
PRIORITY APPLN. INFO.:			US 2002-422531P	P 20021031
			US 2003-666857	A3 20030919
			WO 2003-US29143	W 20030919

OTHER SOURCE(S): MARPAT 140:423660

GI



II

AB The invention relates to title fused heterobicyclic compds. QLWR1R2 (I) [wherein W = 5-6, 6-6, or 5-5 fused bicyclic ring system wherein one or both rings are aromatic, containing N and 0-3 addnl. N, O, or S; R1 = carbamoyl, acyl, hydroxyiminomethyl, acylamino, sulfamoyl, heteroaryl, etc.; R2 = (un)substituted amino, heterocyclyl, OH; L = bond, alkylene, CO, CONR3, SO2NR3, CR3=CR4, O, S, NR3; R3 and R4 = independently H, (cyclo)alkyl, (hetero)aryl(alkyl), heterocyclyl; Q = cycloalkyl, (cyclo)alkenyl, alkynyl, alkoxy, halo, (hetero)aryl, heterocyclyl; with provisos; and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof], which were prepared as inhibitors of IKK α and IKK β enzymes, mediators of TNF- α and IL-1 induced IkB phosphorylation and degradation. For example, reaction of 2-bromo-7-cyano-4-(p-methoxybenzylamino)thieno[3,2-c]pyridine with concentrated H2SO4 gave 2-bromo-7-carboxamido-4-aminothieno[3,2-c]pyridine•H2SO4, which was coupled with 3,4,5-trimethoxybenzeneboronic acid in the presence of K2CO3 and PdCl2(dppf):DCM complex in DMF and H2O to afford II. All exemplified compds. inhibited recombinant, full-length IKK β enzyme with IC50 values of ≤ 10 μ M, and selected compds. displayed IC50 values ≤ 10 μ M against recombinant, full-length IRAK-1 and IRAK-4 enzymes. Thus, I and their pharmaceutical compns. are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious, and cell proliferative diseases or conditions (no data).


IT 690636-53-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of thieno[3,2-c]pyridines and related fused heterobicyclic compds. as antiinflammatory agents)

RN 690636-53-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxamide, 3-amino-5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:120860 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 140:163864

TITLE: Preparation of condensed heterocyclic pyrazole derivatives as protein kinase inhibitors

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala, Valeria; Varasi, Mario

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A, Italy

SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013146	A1	20040212	WO 2003-EP7531	20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, IJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493680	A1	20040212	CA 2003-2493680	20030711
AU 2003250040	A1	20040223	AU 2003-250040	20030711
EP 1530573	A1	20050518	EP 2003-766152	20030711
EP 1530573	B1	20080319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012961	A	20050614	BR 2003-12961	20030711
JP 2005537288	T	20051208	JP 2004-525180	20030711
AT 389658	T	20080415	AT 2003-766152	20030711
ES 2303601	T3	20080816	ES 2003-766152	20030711
MX 2005PA00946	A	20050516	MX 2005-PA946	20050124
US 20060122249	A1	20060608	US 2005-522250	20050919
PRIORITY APPLN. INFO.:			US 2002-398121P	P 20020725
			WO 2003-EP7531	W 20030711
OTHER SOURCE(S):		MARPAT 140:163864		
GI				



AB The title compds. I [wherein X = O, S, SO, SO₂, or NR'; R and R¹ = independently H, (un)substituted R', COR', CO₂R', CONHR', CONR'R'', SO₂R', SO₂NHR', or SO₂NR'R''; R' and R'' = independently H, (un)substituted alkyl, heterocyclyl, aryl, or aralkyl; R₂ = (un)substituted R', CH₂OR', or OR'] or pharmaceutically acceptable salts thereof are prepared. For example, the compound II was prepared in a five-step synthesis starting from Et 4-cyano-5-

(methylthio)thiophene-2-carboxylate. I can be used as protein kinase inhibitors, and are useful for the treatment of cancer (no data).


IT 656235-18-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of condensed heterocyclic pyrazole derivs. as protein kinase inhibitors)

RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:60516 CAPLUS Full-text

DOCUMENT NUMBER: 140:111412

TITLE: Preparation of heterobicyclic pyrazole derivatives as kinase inhibitors

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala, Valeria; Danello, Matteo

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007504	A1	20040122	WO 2003-EP7529	20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492673	A1	20040122	CA 2003-2492673	20030711
AU 2003254337	A1	20040202	AU 2003-254337	20030711
BR 2003012722	A	20050510	BR 2003-12722	20030711
EP 1534716	A1	20050601	EP 2003-763818	20030711
EP 1534716	B1	20080423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501191	T	20060112	JP 2004-520596	20030711
AT 393159	T	20080515	AT 2003-763818	20030711

ES 2304531	T3	20081016	ES 2003-763818	20030711
TW 284645	B	20070801	TW 2003-92119120	20030714
MX 2005PA00629	A	20050425	MX 2005-PA629	20050114
PRIORITY APPLN. INFO.:			US 2002-396174P	P 20020717
			WO 2003-EP7529	W 20030711

OTHER SOURCE(S): MARPAT 140:111412

GI




AB The title compds. [I; X = NR', O, S, SO, SO₂; R, R₁ = H, R', COR', CO₂R', CONHR', CONR'R'', SO₂R', SO₂NHR', SO₂NR'R'' (wherein R', R'' = H, alkyl, aryl, etc.); R₂ = R', CH₂OR', OR'] which may be useful, in therapy, in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer, were prepared E.g., a multi-step synthesis of Me 3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate which showed IC₅₀ of <100 nM, <1000nM, and of <500 nM against Aurora-2, cdc7, and PAK-4, resp., was given. The pharmaceutical compns. comprising the compds. I are disclosed.

IT 648412-09-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterobicyclic pyrazole derivs. as kinase inhibitors)

RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:402031 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:122635
 ORIGINAL REFERENCE NO.: 129:25129a,25132a
 TITLE: The reaction of phenacylmalononitrile with hydrazines: synthesis of new pyridazinones and pyrazolo[1,5-a]pyrimidines
 AUTHOR(S): Elnagdi, Mohamed Hilmy; El-Ghamry, Ibrahim; Kandeel, Ezz; Abdel Rahman, A. H.; Al-Naggar, Abdul Aziz; Amer, Samir; Riad, Mohamed
 CORPORATE SOURCE: Department of Chemistry, Faculty of Science, University of Kuwait, Safat, 13060, Kuwait
 SOURCE: Gazzetta Chimica Italiana (1997), 127(12), 791-794
 CODEN: GCITA9; ISSN: 0016-5603
 PUBLISHER: Societa Chimica Italiana
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:122635
 AB The reaction of phenacylmalononitrile with hydrazine hydrate affords a mixture of 3,5-diamino-4-phenacylpyrazole (I), and 6-oxo-3-phenyl-1,4,5,6-tetrahydropyridazine-5-carbonitrile. The reaction of I with a variety of reagents, that enabled the synthesis of some new pyrazolo[1,5-a]pyrimidine derivs., is described.
 IT 210347-43-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of pyridazinones and pyrazolo[1,5-a]pyrimidines)
 RN 210347-43-6 CAPLUS
 CN 1H-Furo[2,3-c]pyrazol-3-amine, 5-phenyl- (CA INDEX NAME)



IT 210347-42-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of pyridazinones and pyrazolo[1,5-a]pyrimidines)
 RN 210347-42-5 CAPLUS
 CN 1H-Furo[2,3-c]pyrazole-1-propanenitrile, 3-amino-5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:239968 CAPLUS Full-text


DOCUMENT NUMBER: 129:4623
 ORIGINAL REFERENCE NO.: 129:1109a,1112a
 TITLE: Synthesis of thieno-heterocycles from substituted
 5-(methylthio)thiophene-4-carbonitriles
 AUTHOR(S): Briel, D.
 CORPORATE SOURCE: Inst. Pharmazie, Fak. Biowissenschaften, Pharmazie,
 Psychologie, Univ. Leipzig, Leipzig, D-04103, Germany
 SOURCE: Pharmazie (1998), 53(4), 227-231
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 129:4623

AB 5-(Methylthio)-4-thiophenenitriles were used as C3-synthons for the synthesis
 of thienodipyrimidines, thienopyrimidines, thienopyridines, thienopyrazoles,
 and pyrazolothienopyrimidines. The thienopyrazoles and
 pyrazolothienopyrimidines were screened for antiulcer activity.

IT 207452-93-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antiulcer activity)

RN 207452-83-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
 4-(acetylamino)-3-amino-1-methyl-, methyl ester (CA INDEX NAME)




IT 207452-92-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and antiulcer activity)

RN 207452-82-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 4-(acetylamino)-3-amino-,
 methyl ester (CA INDEX NAME)



ORIGINAL REFERENCE NO.: 127:65097a,65100a
 TITLE: Syntheses with heterocyclic β -enamino nitriles.
 An expeditious synthetic approach to polyfunctionally
 substituted 5-phenyl-sulfonylthiophenes and their
 fused derivatives
 AUTHOR(S): Sherif, S. M.; Hussein, A. M.
 CORPORATE SOURCE: Faculty Science, Cairo University, Giza, Egypt
 SOURCE: Monatshefte fuer Chemie (1997), 128(6/7), 687-696
 CODEN: MOCMB7; ISSN: 0026-9247
 PUBLISHER: Springer
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:331458
 GI




AB PhSO₂CH₂COC₆H₄-4-R (R = H, Br) reacts with a mixture of elemental S and CH₂(CN)₂ to yield the corresponding thiophenecarbonitriles I. Compound I (R = H) could be annelated to the corresponding thieno[2,3-d]pyrimidine and thieno[2,3-c]pyrazole (II) upon reaction with the N nucleophiles NH₂CN and NH₂OH.HCl, resp. The applicability and synthetic potency of II to develop a facile convenient route to polyfunctional thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines is reported.

IT 197861-67-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (phenylsulfonyl)thiophenes as heterocyclic enamino nitriles and their fused derivs.)


RN 197861-67-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 4-phenyl-5-(phenylsulfonyl)- (CA INDEX NAME)




L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1995:962283 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 124:176031
 ORIGINAL REFERENCE NO.: 124:32643a,32646a
 TITLE: Thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines and

AUTHOR(S): Briel, D.
 CORPORATE SOURCE: Institut Pharmazie, Universitaet Leipzig, Germany
 SOURCE: Pharmazie (1995), 50(10), 675-8
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 124:176031
 GI



I




II

AB The novel tricyclic ring systems I (R = CO₂Me; R₁ = Me, 2-HOC₆H₄, Ph; X = CH, N) were prepared by reaction of thienopyrazoles II with 1,3-dielectrophiles, such as acetylacetone, dibenzoylmethane, or 1,2,4-dithiazole. Another synthetic route for the preparation of the tricyclic systems, based on pyrazoloazines, was investigated. I and II (R = CO₂Me, COPh) exhibited antiulcer activity.

IT 139299-16-4P 139299-18-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and antiulcer activity of thienopyrazolopyrimidines and -triazines)

RN 139299-16-4 CAPLUS


CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:777293 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 123:340045

ORIGINAL REFERENCE NO.: 123:61027a,61030a

TITLE: Aminothieno[2,3-c]pyrazoles and
aminothieno[2,3-b]pyrroles

AUTHOR(S): Gewald, K.; Rennert, S.; Schindler, R.; Schaefer, H.
CORPORATE SOURCE: Inst. Organische Chem., Technischen Univ., Dresden,
Germany

SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung
(1995), 337(6), 472-7
CODEN: JPCCEM; ISSN: 0941-1216

PUBLISHER: Barth

DOCUMENT TYPE: Journal

LANGUAGE: German

AB The synthesis of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines was described. These compds. were prepared from 3-amino-4-cyano-5-(methylthio)-1,2-dithiol-1-ium iodide as starting material.


IT 139299-12-0P 170953-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)


RN 139299-12-0 CAPLUS

CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA
INDEX NAME)




RN 170953-43-2 CAPLUS


CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX
NAME)



IT 170953-44-3P 170953-45-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)
 RN 170953-44-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carbonitrile, 3,4-diamino- (CA INDEX NAME)



RN 170953-45-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3,4-diamino- (CA INDEX NAME)



L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:106287 CAPLUS Full-text
 DOCUMENT NUMBER: 116:106287
 ORIGINAL REFERENCE NO.: 116:18003a,18006a
 TITLE: Preparation of thieno[2,3-c]pyrazole-3,4-diamines
 Briel, Detlef; Moschke, Thomas; Wagner, Guenther;
 Lohmann, Dieter; Hoffmann, Wolfgang; Ploen, Ursula
 INVENTOR(S): Karl-Marx-Universitaet Leipzig, Germany
 PATENT ASSIGNEE(S): Ger. (East), 6 pp.
 SOURCE: CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 294485	A5	19911002	DD 1990-340708	19900516
PRIORITY APPLN. INFO.:			DD 1990-340708	19900516
OTHER SOURCE(S):			CASREACT 116:106287; MARPAT 116:106287	

GI



AB Title compds. I (R = H, Me; R1 = CO2Me, CO2Et, Bz) were prepared by treating thiophenes II (R2 = alkylsulfonyl) with RNHNH2 with or without isolation of the intermediates II (R2 = NRNH2). Thus, II (R1 = Bz, R2 = MeSO2) was prepared from II (R2 = SH) by methylation and oxidation and was treated with MeNHNH2 in MeOH under reflux followed by HCl-MeOH to give 60% I.HCl (R = Me, R1 = Bz).


IT 139299-12-0P 139299-14-2P 139299-16-4P
139299-18-6P 139299-19-7P 139299-20-0P
139299-21-1P 139299-25-5P 139299-27-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 139299-12-0 CAPLUS

CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX NAME)



RN 139299-14-2 CAPLUS


CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-16-4 CAPLUS


CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-18-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-19-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester
(CA INDEX NAME)




RN 139299-20-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester,
sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 139299-19-7

CMF C7 H8 N4 O2 S



CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 139299-21-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-1-methyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-25-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-27-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-1-methyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:4942 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 106:4942

ORIGINAL REFERENCE NO.: 106:927a,930a

TITLE: Nitriles in heterocyclic synthesis. A novel synthesis of 4-phenacylpyrazole and pyrrolo[2,3-c]pyrazole derivatives

AUTHOR(S): Abdelrazek, Fathy Mohamed; Erian, Ayman Wahba; Hilmy, Khalid Mohamed Hassan

CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt

SOURCE: Synthesis (1986), (1), 74-5



CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:4942

GI




AB PhCOCH₂CH(CN)₂, prepared from PhCOCH₂Br and CH₂(CN)₂, underwent cyclization with RNHNH₂ (R = H, Ph) to give pyrazoles I, which were treated with Cl₃CCN to give pyrrolopyrazoles II.

IT 105576-69-0P 105576-70-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 105576-69-0 CAPLUS

CN Methanone, (3,5-diamino-1,6-dihydropyrrolo[2,3-c]pyrazol-4-yl)phenyl- (CA INDEX NAME)



RN 105576-70-3 CAPLUS

CN Methanone, (3,5-diamino-1,6-dihydro-1-phenylpyrrolo[2,3-c]pyrazol-4-yl)phenyl- (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 09:59:16 ON 13 JAN 2009